About Enzalutamide (Crystalline & Premix) API
Therapeutic Category Oncology
CAS Number
915087-33-1
API Technology
Synthetic
Dose Form
Capsule/ Tablet
Dr Reddy's Development Status
Available
Available Regulatory Filing
USDMF, Brazil DMF, Canada DMF, China DMF, EU
Mechanism of Action
Enzalutamide is an androgen receptor inhibitor that acts on different steps in the androgen receptor signaling pathway. Enzalutamide has been shown to competitively inhibit androgen binding to androgen receptors; and consequently, inhibits nuclear translocation of androgen receptors and their interaction with DNA. A major metabolite, N-desmethyl enzalutamide, exhibited similar in vitro activity to enzalutamide. Enzalutamide decreased proliferation and induced cell death of prostate cancer cells in vitro, and decreased tumor volume in a mouse prostate cancer xenograft model.
Indication
XTANDI is an androgen receptor inhibitor indicated for the treatment of patients with castration-resistant prostate cancer.
Request for Quotation
Get in touch with us by filling out the form below. Our team will reach out to you shortly!
Related APIs
Zoledronic Acid
Oncology
Dasatinib (Monohydrate)
Oncology
Adagrasib
Oncology
Bendamustine Hydrochloride
Oncology
Fruquintinib
Oncology
Venetoclax
Oncology
Tucatinib
Oncology
Ripretinib
Oncology
Azacitidine
Oncology
Bortezomib
Oncology
Cabazitaxel
Oncology
Cabozantinib Hydrochloride
Oncology
Cabozantinib S-Malate
Oncology
Capecitabine
Oncology
Carfilzomib
Oncology
Decitabine
Oncology
Deucravacitinib
Oncology
Eribulin Mesylate
Oncology
Lomustine
Oncology
Nilotinib Hydrochloride Monohydrate (Form B)
Oncology
Olaparib (Form A)
Oncology
Palbociclib
Oncology
Pazopanib
Oncology
Pemetrexed Disodium Heptahydrate
Oncology
Relugolix
Oncology
Acalabrutinib
Oncology
Capivasertib
Oncology
Lenalidomide (Form A)
Oncology
Midostaurin (Amorphous and Form II)
Oncology
Lenvatinib Mesylate (Form C and MIBK Solvate)
Oncology
Enzalutamide (Crystalline & Premix)
Oncology
Pomalidomide
Oncology
Gemcitabine Hydrochloride
Oncology
Apalutamide (Amorphous & Form B)
Oncology
Abiraterone Acetate
Oncology
FAQs
Enzalutamide is a medication used to treat prostate cancer.
-
People with allergies, pregnant or breast feeding should consult the doctor before taking the medicine.
-
Enzalutamide Belongs to class II of BCS classification.
-
Enzalutamide have DMFs filed in the US, Brazil and Canada
-
Store in a dry, cool and well-ventilated place.
-
The dosage form available for Enzalutamide is 160 mg to 240 mg per day.